Abraxis backs SPARC as prognostic biomarker

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.

SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.

Researchers at Abraxis BioScience, the manufacturer of Abraxane (nab-paclitaxel), found that recombinant human SPARC grown in vitro fostered angiogenesis and the development of mature blood vessels. SPARC may play a greater role in the angiogenic process beyond initiating the growth of new blood vessels, they said (abstracts 1478, 2572, 3769, 4017, 5168).

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Video 2 - "MARIPOSA-2 Phase 3 Study Design and Treatment Arms"
Video 1 - "Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies"
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers
Naveen Pemmaraju, MD, with the Oncology Brothers